Singapore markets open in 4 hours 27 minutes
  • Straits Times Index

    -6.89 (-0.21%)
  • S&P 500

    -39.09 (-0.74%)
  • Dow

    -411.32 (-1.06%)
  • Nasdaq

    -99.30 (-0.58%)
  • Bitcoin USD

    -1,029.38 (-1.51%)
  • CMC Crypto 200

    -37.80 (-2.55%)
  • FTSE 100

    -71.11 (-0.86%)
  • Gold

    -20.30 (-0.86%)
  • Crude Oil

    -0.77 (-0.96%)
  • 10-Yr Bond

    +0.0820 (+1.81%)
  • Nikkei

    -298.50 (-0.77%)
  • Hang Seng

    -344.15 (-1.83%)
  • FTSE Bursa Malaysia

    -10.47 (-0.65%)
  • Jakarta Composite Index

    -7,253.63 (-50.39%)
  • PSE Index

    -89.93 (-1.38%)

What's Going On AbbVie Stock On Friday?

What's Going On AbbVie Stock On Friday?
What's Going On AbbVie Stock On Friday?

Friday, AbbVie Inc (NYSE:ABBV) released an interim analysis of an ongoing Phase 3, open-label 156-week extension study evaluating the long-term safety and tolerability of oral atogepant for the prevention of migraine in participants with chronic or episodic migraine.

The shares are trading lower with a session volume of 3.9 million versus the average volume of 5.6 million, as per the data from Benzinga Pro.

Also Read: AbbVie Lifts Long-Term Outlook For New Immunology Drugs, Even As Q4 Revenue and Profit Fall.

The extension study included participants who had enrolled in the Phase 3 PROGRESS and ELEVATE clinical trials with a baseline monthly migraine day burden of 14.5 days and completed these studies.


Key findings from the interim analysis include:

  • Monthly migraine days improved on average by 8.5 days at Weeks 13-16 and this was consistent over 48 weeks.

  • Similar improvements were observed for monthly headache days and monthly acute medication use days.

  • 70% of subjects achieved ≥50% reduction in monthly migraine days at Weeks 13-16, and this was consistent during the 48 weeks of open-label treatment.

Overall safety results were consistent with the known safety profile of atogepant 60 mg, and no new safety signals were identified.

The most common treatment-emergent adverse events (≥5%) were COVID-19 (28.7%), nasopharyngitis (10.9%), and constipation (8.2%).

Atogepant, also known as Qulipta in the U.S. and Aquipta in the European Union (EU), is approved in 45 countries.

In 2023, Qulipta generated sales of $408 million, with fourth-quarter 2023 sales of $114 million.

AbbVie raised its long-term outlook for Ubrelvy and Qulipta revenues and expects peak combined Ubrelvy and Qulipta revenues of more than $3 billion, an increase of approximately $1 billion compared to previous guidance for peak revenues of more than $1 billion for each asset.

Read Next: Biden Administration To Send Pharma Companies Opening Offers For Medicare Program’s First Ever Drug Price Negotiations.

Price Action: ABBV shares are down 2.75% at $162.92 on the last check Friday.

Photo via Shutterstock

"ACTIVE INVESTORS' SECRET WEAPON" Supercharge Your Stock Market Game with the #1 "news & everything else" trading tool: Benzinga Pro - Click here to start Your 14-Day Trial Now!

Get the latest stock analysis from Benzinga?

This article What's Going On AbbVie Stock On Friday? originally appeared on

© 2024 Benzinga does not provide investment advice. All rights reserved.